Latest & greatest articles for omeprazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on omeprazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on omeprazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for omeprazole

21. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. 12501222 2002 12 26 2003 01 02 2015 11 19 1533-4406 347 26 2002 Dec 26 The New England journal of medicine N. Engl. J. Med. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. 2104-10 Current guidelines recommend that patients at risk for ulcer disease who require treatment for arthritis receive (...) nonsteroidal antiinflammatory drugs (NSAIDs) that are selective for cyclooxygenase-2 or the combination of a nonselective NSAID with a proton-pump inhibitor. We assessed whether celecoxib would be similar to diclofenac plus omeprazole in reducing the risk of recurrent ulcer bleeding in patients at high risk for bleeding. We studied patients who used NSAIDs for arthritis and who presented with ulcer bleeding. After their ulcers had healed, we randomly assigned patients who were negative for Helicobacter pylori to receive either

NEJM2002

22. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Healing (...) and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine and placebo: evidence from randomized clinical trials Caro J J, Salas M, Ward A Authors' objectives To estimate the healing and relapse rates in the acute and maintenance treatment of gastroesophageal reflux disease (GERD) with the newer proton-pump inhibitors (PPIs) lansoprazole, rabeprazole and pantoprazole, compared

DARE.2001

23. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia

Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia Kaplan-Machlis B, Spiegler G E, Zodet (...) M W, Revicki D A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology This study considered omeprazole sodium (20 mg once daily) and ranitidine hydrochloride (150 mg twice daily) for the treatment of symptomatic

NHS Economic Evaluation Database.2000

24. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers.

Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. 10922420 2000 08 03 2000 08 03 2014 11 20 0028-4793 343 5 2000 Aug 03 The New England journal of medicine N. Engl. J. Med. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. 310-6 After endoscopic treatment of bleeding peptic ulcers, bleeding recurs in 15 to 20 percent of patients. We assessed whether the use of a high dose (...) of a proton-pump inhibitor would reduce the frequency of recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. Patients with actively bleeding ulcers or ulcers with nonbleeding visible vessels were treated with an epinephrine injection followed by thermocoagulation. After hemostasis had been achieved, they were randomly assigned in a double-blind fashion to receive omeprazole (given as a bolus intravenous injection of 80 mg followed by an infusion of 8 mg per hour for 72 hours) or placebo. After

NEJM2000

25. Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease

Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease Bate C M, Riley S A, Chapman R W G, Durnin A T, Taylor M D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Omeprazole 40mg compared to endoscopy in the initial management of patients with symptoms suggestive of the presence of gastro-oesophageal reflux disease (GERD) based on symptom assessment alone. Type of intervention Diagnosis and treatment. Economic study type Cost-effectiveness analysis. Study population Patients between

NHS Economic Evaluation Database.1999

26. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease

Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease Fass R, Ofman J J, Gralnek I M, Johnson C, Camargo E, Sampliner R E, Fennerty M B Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of omeprazole test (40 mg AM + 20 mg PM for 7 days) as a noninvasive strategy in the diagnosis of gastroesophageal reflux disease (GERD) in patients with typical GERD symptoms. Type of intervention Diagnosis

NHS Economic Evaluation Database.1999

27. Management of acid-related dyspepsia in general practice: cost-effectiveness analysis comparing an omeprazole vs an antacid-alginate/ranitidine management strategy

Management of acid-related dyspepsia in general practice: cost-effectiveness analysis comparing an omeprazole vs an antacid-alginate/ranitidine management strategy Management of acid-related dyspepsia in general practice: cost-effectiveness analysis comparing an omeprazole vs an antacid-alginate/ranitidine management strategy Management of acid-related dyspepsia in general practice: cost-effectiveness analysis comparing an omeprazole vs an antacid-alginate/ranitidine management strategy Mason I (...) , Marchant N J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Management of acid-related dyspepsia in general practice using either omeprazole or antacid-alginate/ranitidine. Type of intervention Treatment. Economic study type Cost

NHS Economic Evaluation Database.1999

28. The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain

The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain Ofman J J, Gralnek I M, Udani J, Fennerty M B, Fass R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The omeprazole test in patients with non-cardiac chest pain. Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study population Hypothetical cohort of patients with non-cardiac chest pain in whom a comprehensive evaluation had excluded a cardiac cause for chest pain. Setting Hospital. The study was carried out in the USA. Dates to which data

NHS Economic Evaluation Database.1999

29. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease

Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease Stalhammar N, Carlsson J, Peacock R, Muller-Lissner S, Bigard M, Porro G B, Ponce J, Hosie J, Scott M, Weir D G, Fulton C, Gillon (...) K, Bardhan K D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of omeprazole (10 or 20 mg once daily) or ranitidine (150 mg twice daily) as initial therapy, and subsequent open maintenance treatment, following initial

NHS Economic Evaluation Database.1999

30. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group.

Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. 10024259 1999 03 24 1999 03 24 2014 06 17 0959-8138 318 7182 1999 Feb 20 BMJ (Clinical research ed.) BMJ Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. 502-7 To assess intermittent treatment over 12 months in patients (...) with symptomatic gastro-oesophageal reflux disease. Randomised, multicentre, double blind, controlled study. Patients with heartburn and normal endoscopy results or mild erosive changes received omeprazole 10 mg or 20 mg daily or ranitidine 150 mg twice daily for 2 weeks. Patients remaining symptomatic had omeprazole 10 mg or ranitidine dose doubled for another 2 weeks while omeprazole 20 mg was continued for 2 weeks. Patients who were symptomatic or mildly symptomatic were followed up for 12 months

BMJ1999 Full Text: Link to full Text with Trip Pro

31. Meta-analyses of cisapride, omeprazole and ranitidine in the treatment of GORD: implications for treating patient subgroups

Meta-analyses of cisapride, omeprazole and ranitidine in the treatment of GORD: implications for treating patient subgroups Meta-analyses of cisapride, omeprazole and ranitidine in the treatment of GORD: implications for treating patient subgroups Meta-analyses of cisapride, omeprazole and ranitidine in the treatment of GORD: implications for treating patient subgroups Iskedjian M, Einarson T R Authors' objectives To examine the efficacy of the pharmocological treatment (...) of gastro-oesophageal reflux disease (GORD) with cisapride, omeprazole or ranitidine. Searching MEDLINE was searched from 1984 to 1995 using the following keywords: 'GERD' (gastroesophageal reflux disease), 'GORD', 'gastroesophageal', 'reflux', 'cisapride', 'ranitidine' and 'omeprazole'. The search was limited to studies in humans, but was not limited to articles published in the English language; articles in French, German and Italian were also included. The bibliographies of the retrieved articles and reviews located

DARE.1998

32. Omeprazole: a review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs

Omeprazole: a review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs Omeprazole: a review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs Omeprazole: a review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs (...) Langtry H D, Wilde M I Authors' objectives To review the use of omeprazole in Helicobacter pylori infections, gastro-oesophageal reflux disease (GORD) and peptic ulcers induced by non steroidal anti-inflammatory drugs. Searching Medical literature published in any language since 1966 was identified using AdisBase (proprietary database of Adis International, New Zealand), MEDLINE and EMBASE. The following terms were used to search AdisBase: omeprazole, gastro- oesophageal reflux, NSAI-induced gastric

DARE.1998

33. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain

The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain Fass R, Fennerty M B, Ofman J J, Gralnek I M, Johnson C, Camargo E, Sampliner R E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of the omeprazole test, compared with placebo, as a diagnostic test for detecting gastroesophageal reflux disease (GERD) in patients with noncardiac chest pain (NCCP). The omeprazole test consisted of a short course of high-dose omeprazole. Type of intervention Diagnosis. Economic

NHS Economic Evaluation Database.1998

34. A cost-utility analysis comparing omeprazole with ranitidine in the maintenance therapy of peptic esophageal stricture

A cost-utility analysis comparing omeprazole with ranitidine in the maintenance therapy of peptic esophageal stricture A cost-utility analysis comparing omeprazole with ranitidine in the maintenance therapy of peptic esophageal stricture A cost-utility analysis comparing omeprazole with ranitidine in the maintenance therapy of peptic esophageal stricture Stal J M, Gregor J C, Preiksaitis H G, Reynolds R P Record Status This is a critical abstract of an economic evaluation that meets (...) data Effectiveness data were identified from a review of previously completed studies Modelling A decision tree model was used to determine the incremental cost utility of omeprazole compared with ranitidine over a one year period. Outcomes assessed in the review The probabilities of patients requiring redilation while receiving either omeprazole or ranitidine over a one year period, the risk of esophageal perforation during dilation or peptic stricture, the probability of surgery following

NHS Economic Evaluation Database.1998

35. Randomised controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis

Randomised controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis Randomised controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis Randomised controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis Laheij R J, Severens J L, Van de Lisdonk E H, Verbeek A L, Jansen J B Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Empirical treatment with omeprazole in patients with persistent dyspeptic symptoms, and, in the case of symptom relapse, serological screening for Helicobacter pylori (H. pylori) infection followed by eradication therapy in seropositive patients

NHS Economic Evaluation Database.1998

36. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. 9494148 1998 03 12 1998 03 12 2013 11 21 0028-4793 338 11 1998 Mar 12 The New England journal of medicine N. Engl. J. Med. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus (...) Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. 719-26 Suppressing acid secretion is thought o reduce the risk of ulcers associated with regular use of nonsteroidal antiinflammatory drugs (NSAIDs), but the best means of accomplishing this is uncertain. We studied 541 patients who required continuous treatment with NSAIDs and who had ulcers or more than 10 erosions in either the stomach or duodenum. Patients were randomly assigned to double-blind treatment with omeprazole, 20 mg

NEJM1998

37. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. 9494149 1998 03 12 1998 03 12 2013 11 21 0028-4793 338 11 1998 Mar 12 The New England journal of medicine N. Engl. J. Med. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group (...) . 727-34 Misoprostol is effective for ulcers associated with the use of nonsteroidal antiinflammatory drugs (NSAIDs) but is often poorly tolerated because of diarrhea and abdominal pain. We compared the efficacy of omeprazole and misoprostol in healing and preventing ulcers associated with NSAIDs. In a double-blind study, we randomly assigned 935 patients who required continuous NSAID therapy and who had ulcers or more than 10 erosions in the stomach or duodenum (or both) to receive 20 mg or 40 mg

NEJM1998

38. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group.

Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. 9862942 1998 12 29 1998 12 29 2013 11 21 0028-4793 339 26 1998 Dec 24 The New England journal of medicine N. Engl. J. Med. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY (...) were randomly assigned to seven days of treatment with 20 mg of omeprazole twice daily, 1000 mg of amoxicillin twice daily, and 500 mg of clarithromycin twice daily or with omeprazole alone and then followed up for one year. Treatment success was defined as the absence of dyspeptic symptoms or the presence of minimal symptoms on any of the 7 days preceding the 12-month visit. Twenty of the 348 patients were excluded after randomization because they were not infected with H. pylori, were not treated

NEJM1998

39. A comparison of omeprazole and placebo for bleeding peptic ulcer.

A comparison of omeprazole and placebo for bleeding peptic ulcer. 9091801 1997 04 10 1997 04 10 2013 11 21 0028-4793 336 15 1997 Apr 10 The New England journal of medicine N. Engl. J. Med. A comparison of omeprazole and placebo for bleeding peptic ulcer. 1054-8 The role of medical treatment for patients with bleeding peptic ulcers is uncertain. We conducted a double-blind, placebo-controlled trial in 220 patients with duodenal, gastric, or stomal ulcers and signs of recent bleeding (...) , as confirmed by endoscopy. In 26 patients the ulcers showed arterial spurting, in 34 there was active oozing, in 35 there were nonbleeding, visible vessels, and in 125 there were adherent clots. The patients were randomly assigned to receive omeprazole (40 mg given orally every 12 hours for five days) or placebo. The outcome measures studied were further bleeding, surgery, and death. Twelve of the 110 patients treated with omeprazole (10.9 percent) had continued bleeding or further bleeding, as compared

NEJM1997

40. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin

Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin Craig A M, Davey P, Malek M, Murray F Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The analysis was carried out for three distinct patient groups: patients with proven

NHS Economic Evaluation Database.1996